CellFE is an innovative startup developing a microfluidics based device to deliver gene-editing molecules.
CellFE enables development and manufacturing of the new generation of medicines – cell therapies.
CellFE was co-founded in 2018 by Alla Zamarayeva, Anna Liu, and Todd Sulchek. The company is headquartered in Alameda, California.
CellFE is focused on the application of microfluidics in the process of delivering gene-editing molecules into human cells.
CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering –efficiently delivering gene-editing molecules into cells while preserving cell viability.
CellFE has completed a $4.8M Series Seed round on Mar 31, 2020. Dynamk Capital and Cota Capital co-led the investment round with participation from Embark Ventures, Elm Ventures and McEwan Lane Family Trust.